Article
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
Leukemia - 1 Mar 2017
Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C
Abstract excerpt
Alterations in TP53 have been described in many cancer types including hematological neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large cohort of patients with hematological malignancies (n=3307), including AML (n=858), MDS (n=943), ALL (n=358), CLL (n=1148). Overall, alterations in TP53 were detected in 332/3307 cases (10%). The highest frequency was observed in ALL (total: 19%;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.